BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 11038003)

  • 1. Blocking catabolism with eniluracil enhances PET studies of 5-[18F]fluorouracil pharmacokinetics.
    Bading JR; Alauddin MM; Fissekis JD; Shahinian AH; Joung J; Spector T; Conti PS
    J Nucl Med; 2000 Oct; 41(10):1714-24. PubMed ID: 11038003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetic modeling of 5-fluorouracil anabolism in colorectal adenocarcinoma: a positron emission tomography study in rats.
    Bading JR; Yoo PB; Fissekis JD; Alauddin MM; D'Argenio DZ; Conti PS
    Cancer Res; 2003 Jul; 63(13):3667-74. PubMed ID: 12839957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action.
    Saleem A; Yap J; Osman S; Brady F; Suttle B; Lucas SV; Jones T; Price PM; Aboagye EO
    Lancet; 2000 Jun; 355(9221):2125-31. PubMed ID: 10902627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extraction of 5-fluorouracil by tumor and liver: a noninvasive positron emission tomography study of patients with gastrointestinal cancer.
    Aboagye EO; Saleem A; Cunningham VJ; Osman S; Price PM
    Cancer Res; 2001 Jul; 61(13):4937-41. PubMed ID: 11431319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous and intra-arterial oxygen-15-labeled water and fluorine-18-labeled fluorouracil in patients with liver metastases from colorectal carcinoma.
    Dimitrakopoulou-Strauss A; Strauss LG; Schlag P; Hohenberger P; Irngartinger G; Oberdorfer F; Doll J; van Kaick G
    J Nucl Med; 1998 Mar; 39(3):465-73. PubMed ID: 9529293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors.
    Adjei AA; Reid JM; Diasio RB; Sloan JA; Smith DA; Rubin J; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Atherton P; Ames MM; Erlichman C
    J Clin Oncol; 2002 Mar; 20(6):1683-91. PubMed ID: 11896120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacokinetic trial of weekly oral fluorouracil given with eniluracil and low-dose leucovorin to patients with solid tumors.
    Grem JL; Harold N; Shapiro J; Bi DQ; Quinn MG; Zentko S; Keith B; Hamilton JM; Monahan BP; Donavan S; Grollman F; Morrison G; Takimoto CH
    J Clin Oncol; 2000 Dec; 18(23):3952-63. PubMed ID: 11099325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005).
    O'Donnell A; Punt CJ; Judson I; Van Maanen L; Suttle AB; Ertel P; Beale P
    Cancer Chemother Pharmacol; 2003 Jan; 51(1):58-66. PubMed ID: 12497207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical development of eniluracil: enhancing the therapeutic index and dosing convenience of 5-fluorouracil.
    Paff MT; Baccanari DP; Davis ST; Cao S; Tansik RL; Rustum YM; Spector T
    Invest New Drugs; 2000 Nov; 18(4):365-71. PubMed ID: 11081572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer.
    Heslin MJ; Yan J; Weiss H; Shao L; Owens J; Lucas VS; Diasio RB
    Cancer Chemother Pharmacol; 2003 Nov; 52(5):399-404. PubMed ID: 12904894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacology of fluorinated pyrimidines: eniluracil.
    Baker SD
    Invest New Drugs; 2000 Nov; 18(4):373-81. PubMed ID: 11081573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sources of error in tissue and tumor measurements of 5-[18F]fluorouracil.
    Harte RJ; Matthews JC; O'Reilly SM; Price PM
    J Nucl Med; 1998 Aug; 39(8):1370-6. PubMed ID: 9708510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil.
    Baker SD; Diasio RB; O'Reilly S; Lucas VS; Khor SP; Sartorius SE; Donehower RC; Grochow LB; Spector T; Hohneker JA; Rowinsky EK
    J Clin Oncol; 2000 Feb; 18(4):915-26. PubMed ID: 10673535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa.
    Harte RJ; Matthews JC; O'Reilly SM; Tilsley DW; Osman S; Brown G; Luthra SJ; Brady F; Jones T; Price PM
    J Clin Oncol; 1999 May; 17(5):1580-8. PubMed ID: 10334547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase.
    Schilsky RL; Kindler HL
    Expert Opin Investig Drugs; 2000 Jul; 9(7):1635-49. PubMed ID: 11060767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic analysis of 5-[18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma.
    Kissel J; Brix G; Bellemann ME; Strauss LG; Dimitrakopoulou-Strauss A; Port R; Haberkorn U; Lorenz WJ
    Cancer Res; 1997 Aug; 57(16):3415-23. PubMed ID: 9270007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil.
    Moehler M; Dimitrakopoulou-Strauss A; Gutzler F; Raeth U; Strauss LG; Stremmel W
    Cancer; 1998 Jul; 83(2):245-53. PubMed ID: 9669806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A possible cause and remedy for the clinical failure of 5-fluorouracil plus eniluracil.
    Spector T; Cao S
    Clin Colorectal Cancer; 2010 Jan; 9(1):52-4. PubMed ID: 20100689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil.
    Shepard DR; Mani S; Kastrissios H; Learned-Coughlin S; Smith D; Ertel P; Magnum S; Janisch L; Fleming GF; Schilsky RL; Ratain MJ
    Cancer Chemother Pharmacol; 2002 May; 49(5):398-402. PubMed ID: 11976834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzyme inhibition as an aid to simplify pharmacokinetic measurements?
    Tewson TJ
    J Nucl Med; 2000 Oct; 41(10):1725-6. PubMed ID: 11038004
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.